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Introduction: Malignant pleural mesothelioma (MPM) is a deadly 
disease with poor prognosis and few treatment options. We charac-
terized and elucidated the roles of C-MYC and PVT1 involved in the 
pathogenesis of MPM.
Methods: We used small interfering RNA (siRNA)-mediated knock-
down in MPM cell lines to determine the effect of C-MYC and PVT1 
abrogation on MPM cells undergoing apoptosis, proliferation, and 
cisplatin sensitivity. We also characterized the expression of microR-
NAs spanning the PVT1 region in MPM cell lines. Copy number 
analysis was measured by quantitative polymerase chain reaction and 
fluorescence in situ hybridization.
Results: Copy number analysis revealed copy number gains (CNGs) 
in chromosomal region 8q24 in six of 12 MPM cell lines. MicroRNA 
analysis showed high miR-1204 expression in MSTO-211H cell lines 
with four copies or more of PVT1. Knockdown by siRNA showed 
increased PARP-C levels in MSTO-211H transfected with siPVT1 
but not in cells transfected with siC-MYC. C-MYC and PVT1 knock-
down reduced cell proliferation and increased sensitivity to cisplatin. 
Analysis of the expression of apoptosis-related genes in the MSTO-
211H cell line suggested that C-MYC maintains a balance between 
proapoptotic and antiapoptotic gene expression, whereas PVT1 and, 
to a lesser extent, miR-1204 up-regulate proapoptotic genes and 
down-regulate antiapoptotic genes. Fluorescence in situ hybridiza-
tion analysis of MPM tumor specimens showed a high frequency of 
both CNGs (11 of 75) and trisomy (three copies; 11 of 75) for the 
C-MYC locus.
Conclusion: Our results suggest that C-MYC and PVT1 CNG pro-
motes a malignant phenotype of MPM, with C-MYC CNG stimulat-
ing cell proliferation and PVT1 both stimulating proliferation and 
inhibiting apoptosis.
Key Words: C-MYC, PVT1, 8q24 chromosomal region, Malignant 
pleural mesothelioma.
(J Thorac Oncol. 2014;9: 998–1007)
Malignant pleural mesothelioma (MPM) is a highly aggressive cancer with a poor prognosis.1 MPM’s inci-
dence in the United States has increased in recent years, and 
2000 to 3000 people are diagnosed with the disease annually.2,3 
MPM predominantly affects men who have been exposed to 
asbestos in an occupational setting.4–8 The risk of developing 
the disease increases with age (median age at diagnosis is 72 
years; range, 45–85 years). MPM’s three major histologic sub-
types are epithelioid, biphasic, and sarcomatoid.1 Epithelioid 
tumors are the most common and have the best prognosis of 
the three subtypes. However, all types are very difficult to 
treat and have a median overall survival (OS) duration rang-
ing from 9 to 17 months,9 with an overall 2-year survival rate 
of only 20%.10 There is therefore a great need to identify new 
therapeutic targets and develop more effective therapies for 
patients with MPM.
A potential therapeutic target for MPM and one of the 
most common chromosomal amplification sites in cancer tis-
sues is the 8q24 region that contains the genes C-MYC and 
PVT1.11–13 C-MYC encodes a transcription factor that regu-
lates the expression of multiple genes involved in cellular 
responses such as growth, proliferation, apoptosis, and dif-
ferentiation.14–16 Deregulated amplification and expression of 
the MYC locus occur in approximately 30% of human can-
cers, including colon, prostate, and breast carcinomas, and 
have been associated with poor prognosis.11,17,18 PVT1 is a 
candidate oncogene located adjacent to the MYC locus on 
chromosomal region 8q24.18–20 PVT1 has been shown to act 
as a noncoding RNA with many alternatively spliced iso-
forms.12,21 The PVT1 locus has recently been found to con-
tain a cluster of at least six microRNAs (miRNAs) (such as 
miR-1204, -1205, -1206, -1207-3p, -1207-5p, and -1208) 
that span the PVT1 region, adding further complexity to the 
locus.12,21 Both PVT1 copy number gains (CNGs) and PVT1 
overexpression have been implicated in the pathophysiol-
ogy of many tumors, including breast and ovarian cancers 
and acute myeloid leukemia.19,22 In addition, PVT1 altera-
tion has been shown to contribute to tumor survival and 
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chemoresistance.22,23 However, the roles that MYC, PVT1, 
and miRNAs contained in the 8q24 chromosomal region play 
in MPM remain unclear. We therefore sought to elucidate 
these roles and the specific mechanisms of action of C-MYC 
and PVT1 involved in the pathogenesis of MPM.
In the present study, we characterized the molecular 
abnormalities found in the 8q24 locus in MPM cell lines and 
in specimens from surgically resected MPMs and character-
ized the miRNA (miR-1204, -1205, 1206, -1207-3p, 1207-5p, 
and -1208) expression in MPM cell lines. We also determined 
the biological impact of small interfering RNA (siRNA)-medi-
ated C-MYC and PVT1 abrogation on MPM cellular processes 
such as apoptosis, cell proliferation, and response to cisplatin 
and then determined the effect of C-MYC, PVT1, and miR-
1204 knockdown on the expression levels of apoptosis-related 
genes. Finally, we studied C-MYC and PVT1 copy number and 
gene expression in MPM tumor specimens.
MATERIALS AND METHODS
Tumors Specimen and Cell Lines
From the tissue bank at The University of Texas M. D. 
Anderson Cancer Center, we obtained archived frozen and 
formalin-fixed, paraffin-embedded tissues for patients who had 
undergone surgical resection for MPM. We randomly selected 
75 MPM samples of different histologic subtypes (37 epithe-
lioid, 26 biphasic, and 12 sarcomatoid) for analysis. Detailed 
clinical and pathologic information on the patients is presented 
in Supplementary Table 1 (Supplementary Digital Content 1, 
http://links.lww.com/JTO/A598). The study protocol was 
approved by the M. D. Anderson Institutional Review Board. 
Of the 12 MPM cell lines used in this study, five (H2452, 
MET-5A, H2052, H28, and MSTO-211H) were obtained from 
the American Type Culture Collection (Manassas, VA) and cul-
tured in RPMI 1640 (Cellgro Mediatech, Manassas, VA) and 
seven (HCT-4012, Meso, HP3, HP5, HP7, HP9, and HP10) were 
acquired from Dr. Harvey Pass (New York University, New York, 
NY) and cultured in high-glucose Dulbecco’s modified Eagle’s 
medium (Cellgro Mediatech). All media formulations included 
10% fetal bovine serum and antibiotics (Sigma-Aldrich, St. 
Louis, MO). All MPM cell lines had been tested for absence 
of mycoplasma using Universal Mycoplasma Detection Kit 
according to the manufacturer’s instructions (ATCC, Manassas, 
VA) and cells were authenticated at University of Texas M.D. 
Anderson Cancer Center Core Facility.
Isolation of DNA and Copy Number Profiling
DNA was extracted from cell lines using DNAzol 
Reagent (Life Technologies, Grand Island, NY), and whole-
genome single nucleotide polymorphism (SNP) array profil-
ing was performed using Affymetrix SNP 6.0 chips (Agilent 
Technologies, Santa Clara, CA) in five MPM cell lines. 
CNGs were identified using the SNP-Fast Adaptive States 
Segmentation Technique 2 algorithm in Nexus 5.1 software 
(BioDiscovery, Hawthorne, CA) with the significance thresh-
old for segmentation setting at p < 5 × 10−7. CNGs were defined 
with log2 ratio values of 0.2, and two or more than two CNGs 
were defined by log2 ratio values of 0.7.
Copy Number Analysis
We used fluorescence in situ hybridization (FISH) and 
real-time quantitative polymerase chain reaction (q-PCR) 
analyses to quantify 8q24 CNGs in MPM tumor speci-
mens. We used directly labeled fluorescent chromosomal 
centromeric probes (CEP 8; SpectrumGreen; Vysis, Abbott 
Laboratories, Chicago, IL) for chromosome 8 and locus-
specific probes for regions 8q24.12-q13 (C-MYC Spectrum 
Orange) (Vysis; Abbott Laboratories, Chicago, IL). FISH 
was performed according to the manufacturer’s instructions. 
Copy number analysis was performed in 50 nuclei per tumor 
in at least four areas. Copy number alteration was defined as 
the presence of more than two gene copies per cell on aver-
age of the 50 cells. Trisomy was defined as the presence of 
three copy number alterations and CNG was defined as the 
presence of at least four copies. To enrich for malignant 
cell content for q-PCR analysis, tumor tissues were manu-
ally microdissected for subsequent DNA extraction from 
formalin-fixed, paraffin-embedded tissue sections. Tumor 
DNA was extracted using the Pico Pure DNA Extraction Kit 
(Arcturus; Life Technologies) according to the manufacturer’s 
instructions. DNA samples with proportions of microdis-
sected tumor cell greater than 70% were qualified for q-PCR 
analysis. MYC and PVT1 gene copy numbers were exam-
ined by q-PCR using the comparative Ct method using the 
ABI 7300 real-time PCR system (Applied Biosystems, Grand 
Island, NY). The sequences of PCR primers used to CNG 
were for C-MYC: 5’-TCAAGAGGTGCCACGTCTCC-3’ 
and 5’-TCTTGGCAGCAGGATAGTCCTT-3’ (flanking exon 
3), and for PVT1: 5’-ACAGTGATCTTCAGTGGTCTGG-3’ 
and 5’-CGTGTGTCATTCCAGTGCAT-3’ (flanking exon 2). 
Each PCR was carried out using Power SYBR Green PCR 
Master Mix (Applied Biosystems) at 50°C for 2 minutes and 
95°C for 10 minutes followed by 40 cycles at 95°C for 15 
seconds and 60°C for 1 minute. β-Actin was introduced as 
the endogenous reference gene, and TaqMan Control Human 
Genomic DNA (Applied Biosystems) was amplified as a stan-
dard control for calibration. MYC and PVT1 gene copy num-
ber in normal human genomic DNA was set as 2, and copy 
number 4 or more was considered as CNG.24 All sample and 
standard DNA reactions were set in triplicate to gauge reac-
tion accuracy.
Isolation of mRNA and miRNA Analysis
Total RNA was extracted from frozen MPM tumor spec-
imens and cell lines using TRI Reagent (Life Technologies). 
Spectrophotometric analysis using Nanodrop 1000 (Nanodrop; 
Thermo Fisher Scientific, Waltham, MA) was used to quan-
tify RNA, and Agilent BioAnalyzer RNA nano-chips (Agilent 
Technologies) were used to gauge RNA quality. Affymetrix 
U133 Plus 2.0 gene expression arrays (Affymetrix, Santa 
Clara, CA) were used to determine global expression lev-
els of genes, including MYC and PVT1 in the total RNA 
extracted from tumor specimens. Using a High Capacity 
RNA-to-cDNA Kit and Taqman Gene Expression PCR Assays 
(Applied Biosystems), we performed quantitative reverse 
transcriptase (qRT) PCR analysis of the RNA extracted from 
cell lines to quantify MYC and PVT1 levels. The sequences 
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of PCR primers used to gene expression were for C-MYC: 
5’-CAGCTGCTTAGACGCTGGATT-3’ (flanks between 
exon 1 and 2) and 5’-GTAGAAATACGGCTGCACCGA-3’, 
for PVT1: 5’-TTACAGGCGTGTGCCACAAAGC-3’ and 
5’-GCCTGTAATCCCAGCACGTTGA-3’ (flanks between 
exon 5 and 6). Glyceraldehyde 3-phosphate dehydrogenase 
was used as the endogenous control. TaqMan microRNA 
assays (Applied Biosystems) were used to quantify the lev-
els of miRNAs (miR-1204, -1205, -1206, -1207-3p, -1207-
5p, and -1208) with U6 as the endogenous control. Standard 
PCR assays were performed on triplicate samples in standard 
cycling conditions using the ABI PRISM 7300 Sequence 
Detection System (Applied Biosystems). This process was 
used to yield relative expression levels using the 2(−∆∆C
T
) 
method with the help of ABI 7300 System SDS v1.4 software 
(Applied Biosystems).
TaqMan Human Apoptosis Array
TaqMan gene expression assays were used along with 
the three control genes (18S, ACTB, and GAPDH) to detect the 
expression levels of the 93 apoptosis-related genes on a micro 
fluidic 384-well array (TaqMan Array Human Apoptosis; 
Applied Biosystems), using an Applied Biosystems 7900HT 
Fast Real-Time PCR System (Applied Biosystems; Life 
Technologies). Fold changes of gene expression in experi-
mental samples were quantified relative to the control samples 
using the equation 2(−∆∆C
T
). Data were analyzed using Data 
Assist Software version 3.0 (Life Technologies) and a two-
fold change in gene expression was defined as the threshold 
for up- or down-regulation.
MTS Assay
Cisplatin was purchased from Selleck Chemicals 
(Houston, TX). To determine the median half-maximal inhibi-
tory concentration (i.e., IC
50
), cells were seeded in octuplicate 
at a density of 2000 per well in 96-well plates. After 24 hours, 
Cells were treated with increasing concentrations (0–30 μM) of 
drugs. An end point viability assay using MTS (3-4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt) assays (Promega, San Luis Obispo, 
CA) was performed after 72 hours of drug treatment.
siRNA Transfection and Cell Proliferation Assays
Cell lines were transfected with two gene-specific 
siRNA duplexes for each gene (C-MYC and PVT1) and control 
siRNA (Ambion, Grand Island, NY) at a final concentration of 
10 nmol per liter using Lipofectamine RNAiMAX (Invitrogen, 
Grand Island, NY) according to the manufacturer’s instruc-
tions. To verify the knockdown’s efficiency, we collected the 
mRNAs and protein of transfected cells and subjected them 
to qRT-PCR and Western blot analyses. miRNA inhibitor 
anti-miR-1204 was used to down-regulate miR-1204 expres-
sion in MSTO-211H MPM cell line and the miRNA inhibitor 
negative control, at a final concentration of 50 nmol per liter 
using Lipofectamine RNAiMAX (Invitrogen) according to the 
manufacturer’s instructions. miRNA inhibition by anti-miRNA 
was assessed by TaqMan microRNA Assays with U6 as the 
endogenous control (Applied Biosystems). Proliferation 
assays were carried out by MTS assay according to the manu-
facturer’s protocols (Promega). Western blot analysis was car-
ried out by using specific antibodies against C-MYC (Santa 
Cruz Biotechnology, Santa Cruz, CA) and the analysis cleaved 
poly(ADP-ribose) polymerase (PARP-cleaved; Asp214; Cell 
Signaling Technology, Danvers, MA) and cleaved Caspase 3 
(Cleaved Casp3; Asp175; Cell Signaling Technology).
Statistical Analysis
Data obtained from cell culture assays and from the 
qRT-PCR and Western blot analyses were summarized using 
descriptive and inferential statistics accompanied by graphs 
of relative expression created using the Prism software pro-
gram (version 5.0; GraphPad Software, La Jolla, CA). DNA 
copy number analysis using Affymetrix SNP6.0 microarray 
chip was conducted on Nexus 5.1 software (BioDiscovery). 
Demographic and clinical information for the patients whose 
archived tumor samples were analyzed using the chi-square, 
Fisher’s exact, Wilcoxon rank-sum, and Kruskal-Wallis tests. 
OS and recurrence-free survival distributions were estimated 
using the Kaplan–Meier method and compared between 
groups of patients using the log-rank test. Cox proportional 
hazard models were used to calculate OS duration data, which 
was defined as the time from surgery to the patient’s death or 
last contact, and for recurrence-free survival duration, which 
was defined as the time from surgery to tumor recurrence or 
the patient’s last contact.
RESULTS
8q24 Locus Amplification and C-MYC and 
PVT1 Expression in MPM Cell Lines
We performed global SNP/copy number analysis using 
Affymetrix SNP 6.0 chips in four MPM cell lines (H28, 
MSTO-211H, H2052, and H2452) and, for comparison, in the 
control normal cell line HCC-4012 (a telomerase-transformed 
pleural mesothelial cell line). DNA copy number analysis 
revealed CNG of chromosomal region 8q24, which contains 
both the C-MYC and PVT1 genes, in three of the five MPM 
cell lines (MSTO-211H, H2052, and H2452) relative to the 
control cell line (HCC-4012; Fig. 1A, B). To confirm our find-
ing of CNG of the C-MYC locus in MPM cell lines, we per-
formed FISH and q-PCR analyses on 12 MPM cell lines. FISH 
analysis revealed a relatively high frequency of CNG defined 
as four copies or more of the C-MYC locus (6 of 12, 50%; 
Fig. 1C). Similarly, q-PCR analysis of genomic DNA showed 
a high frequency (5 of 12, 42%) of C-MYC CNG, also defined 
as four copies or more (Fig. 1D). We also used q-PCR to quan-
tify CNG for the PVT1 gene, again detecting a high frequency 
(5 of 12, 42%) of PVT1 CNG (Fig. 1D). Interestingly, C-MYC 
and PVT1 CNGs were always detected in the same cell lines 
(H2452, MET-5A, H2052, HP10, and MSTO-211H). Of these 
cell lines, only HP10 and MSTO-211H had amplification for 
C-MYC (>15 copies).
To determine whether C-MYC and PVT1 expression 
levels were also increased in MPM cell lines, we analyzed 
mRNA expression using qRT-PCR of both genes on 12 MPM 
cell lines. qRT-PCR analysis showed increased levels (i.e., 
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FIGURE 1. C-MYC locus amplification is observed in MPM cell lines but not in normal mesothelial cell lines. A, SNP/copy num-
ber analysis by Nexus 5.1 software showed amplification (represented as green bars) of chromosomal region 8q24.21 that con-
tains the oncogene C-MYC. Duplicate samples of MPM cell line MSTO-211H were compared with normal cell line HCC-4012. 
B, Copy number analysis by Nexus 5.1 software showed C-MYC locus amplification in a representative sample of the MSTO-
211H cell line. C, Representative examples of C-MYC copy number examined by FISH in MPM cell lines. a, An H28 specimen 
shows no CNG. b, An MSTO-211H specimen shows CNG. Red signals represent the C-MYC gene probe, whereas green signals 
represent the internal control probe (magnification 1,000×). D, q-PCR analysis of C-MYC and PVT1 CNG in MPM cell lines. E, 
Relative expression of C-MYC and PVT1 mRNA by qRT-PCR in MPM cell lines showed increased levels (i.e., ≥4-fold changes) of 
C-MYC gene expression in five MPM cell lines (HP3, HP7, H28, H2052, and MSTO-211H), and only the MSTO-211H cell line 
showed an increased level of PVT1gene expression (≥4-fold change). F, Relative expression of miRNAs by qRT-PCR in MPM cell 
lines showed expression of miR-1204, -1205, -1207-5p, and -1208 in all seven MPM cell lines and not detect miR-1206 or miR-
1207-3p expression in any of the cell lines tested. FISH, fluorescence in situ hybridization; MPM, malignant pleural mesotheli-
oma; miRNA, microRNA; SNP, single nucleotide polymorphism; CNG, copy number gain; q-PCR, quantitative polymerase chain 
reaction; qRT-PCR, quantitative reverse transcriptase polymerase chain reaction.
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≥4-fold changes) of C-MYC gene expression in five MPM 
cell lines (HP3, HP7, H28, H2052, and MSTO-211H). For 
the PVT1 gene, only the MSTO-211H cell line with CNG for 
PVT1 showed an increased level of gene expression (≥4-fold 
change) (Fig. 1E). We did not detect increased levels of PVT1 
gene expression in the other MPM cell lines those had CNG 
for PVT1.
miRNA Expression in the PVT1 
Region in MPM Cell Lines
PVT1 encodes a noncoding RNA and is a host gene for 
the following several miRNAs, including miR-1204, -1205, 
-1206, -1207-3p, -1207-5p, and -1208. We screened a panel 
of seven MPM cell lines for expression of miR-1204, -1205, 
-1206, -1207-3p, -1207-5p, and -1208 in the PVT1 region 
using qRT-PCR. We detected expression of miR-1204, -1205, 
-1207-5p, and -1208 in all seven MPM cell lines (Fig. 1F 
and Supplementary Table 2, Supplementary Digital Content 
1, http://links.lww.com/JTO/A598). We did not detect miR-
1206 or miR-1207-3p expression in any of the cell lines 
tested. Interestingly, the MSTO-211H cell line with PVT1 
CNG showed an increased expression of miR-1204 (≥4-fold 
change) and miR-1208 (≥2-fold change). In addition, we 
detected a relatively high expression of miR-1205 in HP10 
(≥3-fold change).
The Roles of C-MYC and PVT1 in Oncogenesis
To examine the effects of abrogation of C-MYC and 
PVT1 function in MPM cell lines, we knocked down C-MYC 
and PVT1 in the MSTO-211H and H28 MPM cell lines using 
specific siRNA. Cell lines were selected for their numbers of 
C-MYC and PVT1 CNG (>10 copies and <4 copies, respec-
tively). In both cell lines, qRT-PCR analysis showed that 
C-MYC and PVT1 knockdown significantly decreased mRNA 
expression relative to control siRNA-transfected and nontrans-
fected cells (Fig. 2A, B). We first assessed the cytotoxic effects 
of C-MYC and PVT1 knockdown on MPM cell lines by induc-
ing apoptosis (Fig. 2C, D). We found that PVT1 knockdown 
increased PARP-cleaved and cleaved Caspase 3 expression 
in the MSTO-211H cell line relative to control siRNA-trans-
fected and nontransfected cells 72 hours after transfection 
(Fig. 2C and Supplementary Figure 2, Supplementary Digital 
Content 2, http://links.lww.com/JTO/A599). After transfec-
tion of siC-MYC, we observed a decrease, rather than an 
increase, in PARP-cleaved levels (Fig. 2C). We did not detect 
changes in PARP-cleaved levels under any treatment of the 
H28 cell line (Fig. 2D). Interestingly, we found that C-MYC 
knockdown by siRNA induced a decrease in PVT1 expres-
sion in the MSTO-211H and H28 cell lines, suggesting that 
C-MYC might regulate PVT1 expression in the MSTO-211H 
cell lines (Fig. 2A, B).
We additionally investigated the effect of C-MYC and 
PVT1 knockdown by siRNA on cell proliferation. We found 
significant proliferation inhibition in the MSTO-211H cell 
line when knocked down C-MYC and PVT1 (Fig. 2E) rela-
tive to the control siRNA-transfected and nontransfected cells 
(Fig. 2E). Proliferation was more strongly inhibited when we 
knocked down PVT1 than when we knocked down C-MYC in 
the MSTO-211H cell line. Inhibition of cell proliferation was 
not observed in the H28 cell line when knocked down C-MYC 
and PVT1 (Fig. 2F).
We then evaluated the effect of C-MYC and PVT1 knock-
down by siRNA on the MPM cell lines’ sensitivity to cisplatin. 
Upon treatment with siC-MYC and siPVT1, the MSTO-211H 
cell lines were significantly more sensitive to cisplatin in vitro 
(Fig. 2G; p < 0.05) than were the control siRNA-transfected 
and nontransfected cells. This increased cisplatin sensitiv-
ity was not observed in H28 cells transfected with siC-MYC 
and siPVT1 (Fig. 2H). These findings suggest that depletion 
of C-MYC and PVT1 significantly contributes to increases in 
the sensitivity of MPM cell lines with 8q24 amplification in 
response to cisplatin.
We also analyzed the effect of miR-1204 down-reg-
ulation by anti-miR-1204 on cell proliferation and cisplatin 
sensitivity in MSTO-211H MPM cell lines. qRT-PCR showed 
that anti-miR-1204 significantly decreased miR-1204 expres-
sion relative to control cells transfected with control anti-
miRNA and nontransfected cells (Supplementary Figure 1A, 
Supplementary Digital Content 2, http://links.lww.com/JTO/
A599). However, we found no significant differences between 
cells treated with anti-miR-1204, control cells transfected with 
control anti-miRNA, and nontransfected cells in terms of cis-
platin sensitivity (Supplementary Figure 1B, Supplementary 
Digital Content 2, http://links.lww.com/JTO/A599) and pro-
liferation (Supplementary Figure 1C, Supplementary Digital 
Content 2, http://links.lww.com/JTO/A599). These finding 
suggest that changes in apoptosis and cisplatin sensitivity pro-
duced by PVT1 are not mediated by miR-1204; rather, these 
PVT1-driven changes may be mediated, either individually or 
jointly, by other miRNAs spanning the PVT1 region.
Overall, our in vitro analysis strongly supports our 
hypothesis that 8q24 amplification can contribute to different 
oncogenic functions in MPM cancer cells. Specifically, CNGs 
of C-MYC stimulates cell proliferation, and CNGs of PVT1 
stimulates proliferation and inhibits apoptosis.
Regulation of Apoptosis-Related Gene 
Expression by C-MYC and PVT1
Our in vitro findings demonstrate that PVT1 knockdown 
increases PARP-cleaved and cleaved Caspase 3 expression in 
the MSTO-211H cell line. In contrast, after C-MYC knock-
down, we observed a decreased PARP-cleaved expression. 
The effects of C-MYC and PVT1 knockdown suggest that 
although both genes regulate apoptosis, they do so by alterna-
tive means. To understand how these genes are orchestrated 
to regulate apoptosis, we used the TaqMan Human Apoptosis 
Array to study the expression of 93 genes involved in apop-
tosis in two MPM cell lines with C-MYC and PVT1 CNGs: 
MSTO-211H cell line transfected with siC-MYC, siPVT1, and 
anti-miR-1204 and HP10 cell line transfected with siC-MYC 
and siPVT1.
Table 1 and Supplementary Table 3 (Supplementary 
Digital Content 1, http://links.lww.com/JTO/A598) depict 
changes in the expression levels of apoptosis-related genes 
after knockdown of C-MYC, PVT1, and miR-1204 (≥2-
fold change of expression). Knockdown of C-MYC in the 
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FIGURE 2.  Knockdown of C-MYC and PVT1 by small interfering RNA (siRNA) decreased expression of C-MYC and PVT1, 
increased sensitivity to cisplatin, and reduced cell proliferation in MPM cell lines. A, qRT-PCR analisys of C-MYC and PVT1 
 expression showed decreased C-MYC and PVT1 expression after knockdown of C-MYC and PVT1 by siRNAs in the MSTO-211H 
cell line. B, H28 MPM cell lines showed decreased C-MYC and PVT1 expression after knockdown of C-MYC and PVT1 by siRNAs. 
***p < 0.001, **p < 0.01, *p < 0.05. C, Western blot analysis of C-MYC and PARP-C expression after knockdown of C-MYC and 
PVT1 in MST0-211H cell lines showed decreased expression of C-MYC and increased PARP-C levels. D, Knockdown of C-MYC 
and PVT1 by siRNAs in H28 MPM cell lines showed decreased expression of C-MYC and not detect changes in PARP-C levels 
when knocked down C-MYC and PVT1 in the H28 cell line. E, Knockdown of C-MYC and PVT1 significantly reduced cell prolif-
eration in MSTO-211H. **p < 0.01. F, However, proliferation was not reduced in H28 MPM cell lines. G, Knockdown of C-MYC 
and PVT1 by siRNA caused a 1.9-fold (p < 0.05) and 1.7-fold (p < 0.05) decrease in the cisplatin IC50 in MSTO-211H cell lines. 
H, However, knockdown did not cause cisplatin IC50 to decrease in H28 MPM cell lines. MPM cells subjected to gene-specific 
siRNA experiments were compared with control siRNA-transfected and nontransfected cells. MPM, malignant plural mesothe-
lioma; qRT-PCR, quantitative reverse transcriptase polymerase chain reaction.
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MSTO-211H cell line reveals seven genes that were up-reg-
ulated (LTB, BIRC7, BCL2L14, PYCARD, BCL2A1, FASLG, 
and BIRC2) and three genes that were down-regulated 
(NFKB1, BBC3, and TNFRSF21) relative to nontransfected 
cells or cells transfected with scrambled siRNA (control). Of 
the up-regulated genes, four have known apoptotic functions 
(LTB, BCL2L14, PYCARD, and FASLG) and the remaining 
three (BIRC7, BCL2A1, and BIRC2) have known antiapop-
totic function. Among the down-regulated genes, one gene 
(NFKB1) has antiapoptotic function and two genes (BBC3 and 
TNFRSF21) have proapoptotic function. PVT1 knockdown 
up-regulated five genes (LTB, BCL2L14, PYCAR, FASLG, and 
TNFRSF1B) and down-regulated six genes (BCL2L1, BCL2, 
ICEBERG, CASP5, TNF, and BIRC8) relative to the expres-
sion levels of nontransfected cells or cells transfected with 
scrambled siRNA (i.e., controls). All genes whose expres-
sion was enhanced by PVT1 knockdown have proapoptotic 
function. Four of the down-regulated genes (BCL2L1, BCL2, 
ICEBERG, and BIRC8) have antiapoptotic function, whereas 
the other two down-regulated genes (CASP5 and TNF) have 
proapoptotic function. Knockdown of C-MYC and PVT1 in 
the HP10 cell line revealed a similar tendency of genes up-reg-
ulated and down-regulated, but less pronounced. Interestingly, 
one of the most highly up-regulated genes in HP10 cell line 
was LTB gene which is also up-regulated in MSTO-211H cell 
line after C-MYC and PVT1 knockdown.
We also investigated whether miR-1204 down-regula-
tion using anti-miR-1204 in the MSTO-211H cell line regu-
lated the expression of apoptosis-related genes. miR-1204 
down-regulation increased the expression of five genes (LTB, 
BIRC7, BCL2L14, PYCAR, and BIRC2) and decreased the 
expression of three genes (ICEBERG, CASP5, and BIRC8). 
Three of the up-regulated genes (LTB, BCL2L14, and PYCAR) 
have proapoptotic function, whereas the other two up-regu-
lated genes (BIRC7 and BIRC2) are involved in antiapoptotic 
function. Two of the down-regulated genes (ICEBERG and 
BIRC8) have known antiapoptotic function, and the other 
down-regulated gene (CASP5) has proapoptotic function.
We found that C-MYC knockdown affected the expres-
sion of several pro- and antiapoptotic genes and thus main-
taining a balance between these genes. PVT1 knockdown 
appeared to up-regulate proapoptotic genes and down-reg-
ulate antiapoptotic genes. These results are in accordance 
with our observation of an apoptotic phenotype of increased 
PARP-cleaved expression in the MSTO-211H cell line after 
PVT1 knockdown—an effect we did not observe after C-MYC 
knockdown.
C-MYC CNG in MPM Tumors
To validate the C-MYC CNG results obtained in MPM 
cell lines, we determined the gene copy number of the C-MYC 
locus in MPM tumor tissue specimens by performing FISH 
using the C-MYC probe on tissue microarrays containing 75 
MPM samples from different histologic subtypes (37 epitheli-
oid, 26 biphasic, and 12 sarcomatoid). FISH analysis of tissue 
microarrays revealed a high frequency of CNGs (11 of 75, 
15%, ≥4 copies) and of trisomy (11 of 75, 15%, 3 copies) 
in the C-MYC locus in the MPM tumors. Interestingly, these 
CNGs were seen in the biphasic (6 of 26, 23%) and epithelioid 
(5 of 37, 13%) histotypes but not in the sarcomatoid cases 
TAbLE 1.  Gene Expression of Apoptosis-Related Genes after Knockdown C-MYC, PVT1, and miR-1204 in MSTO-211H Cell Lines
Fold Change
Gene Name siC-MYC siPVT1 Anti-miR-1204 Gene Description Function
Genes up-regulated
  LTB 17.56 7.31 5.25 Lymphotoxin beta Proapoptotic
  BIRC7 9.96 −1.61 8.83 Baculoviral IAP repeat-containing protein 7 Antiapoptotic
  BCL2L14 9.43 4.35 6.57 BCL2 like protein 14 Proapoptotic
  PYCARD 9.59 −4.06 9.92 PYD and card domain–containing protein Proapoptotic
  BCL2A1 3.79 −1.23 1.41 BCL2-related protein A1 Antiapoptotic
  FASLG 3.29 3.03 1.27 FAS ligand Proapoptotic
  BIRC2 2.93 1.66 2.22 Baculoviral IAP repeat-containing protein 2 Antiapoptotic
  TNFRSF1B 0.89 2.12 1.50 Tumor necrosis factor receptor superfamily member 1B Proapoptotic
Genes down-regulated
  NFKB1 −2.15 1.49 1.01 NF-kappa-B p105 subunit Antiapoptotic
  BBC3 −2.20 −1.17 1.01 BCL2 binding component 3 Proapoptotic
  TNFRSF21 −2.50 1.21 −1.75 Tumor necrosis factor receptor superfamily member 21 Proapoptotic
  BCL2L1 1.11 −2.02 −1.35 BCL2 like 1 Antiapoptotic
  BCL2 −1.47 −2.13 −1.05 B-cell lymphoma 2 Antiapoptotic
  ICEBERG 1.26 −6.95 −5.31 Caspase 1 inhibitor Antiapoptotic
  CASP5 −1.08 −9.52 −2.47 Caspase 5, apoptosis-related cysteine protease Proapoptotic
  TNF −1.43 −11.48 −1.62 Tumor necrosis factor Proapoptotic
  BIRC8 1.10 −42.69 −2.47 Baculoviral IAP repeat-containing protein 8 Antiapoptotic
Bold: ≥2-fold change of expression, p < 0.05.
IAP, inhibitors of apoptosis protein; NF, nuclear factor; PYD, PYRIN-PAAD-DAPIN domain.
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(Fig. 3A–C). Trisomy was seen in biphasic (6 of 26, 23%), 
epithelioid (3 of 37, 8%), and sarcomatoid (2 of 12, 17%) his-
totypes. In addition, we investigated the association between 
C-MYC CNG detected by FISH and clinicopathological fea-
tures of resected MPM tissue specimens. We did not find any 
correlation between C-MYC CNGs with clinicopathological 
features. After adjustment for age, tumor size, OS, stage, and 
adjuvant therapy, multivariate analysis did not show any corre-
lation between C-MYC CNGs and patient outcome (p > 0.75).
To confirm the C-MYC CNG results obtained using 
FISH, we used q-PCR to determine gene copy numbers in 30 
tumor specimens (11 with C-MYC FISH-detected CNG and 
19 without C-MYC FISH-detected CNG). C-MYC CNGs (≥4 
copies) were detected by q-PCR in 12 MPM specimens (10 
with C-MYC CNG and 2 without C-MYC CNG detected on 
the FISH results; Fig. 3D). In addition, we also used q-PCR 
to detect PVT1 CNG in the same 30 tumor specimens. PVT1 
CNG was detected in 12 MPM specimens (8 with C-MYC 
CNG and 3 without C-MYC CNG based on the FISH results; 
Fig. 3E).
We additionally determined C-MYC and PVT1 mRNA 
expression levels in a subset of 55 MPM tumor specimens 
paired with 41 normal tissues from our database using 
Affymetrix U133 plus 2.0 chips. We found significant dif-
ferences in C-MYC and PVT1 gene expression between the 
normal tissues and the tumor samples (Fig. 3F, G; p < 0.05).
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FIGURE 3.  MPM tumor tissue specimens show C-MYC and PVT1 locus–specific CNG and high expression of C-MYC and PVT1. 
Representative examples of C-MYC CNG examined by FISH in MPM tissue specimens show high frequency of CNGs. FISH 
analysis shows A CNGs in epithelioid MPM. B, CNGs in biphasic MPM. C, No CNG in sarcomatoid MPM. Red signals represent 
the C-MYC gene probe, whereas and green signals represent the internal control probe (magnification 1,000×). Real-time q-PCR 
analysis of CNG of C-MYC and PVT1 in MPM tumor specimens by compared with CNG by FISH shows a correlation between 
both approaches. D, The box plots depict relative CNG of C-MYC revealed by q-PCR in 11 MPM tumor cell lines with C-MYC 
CNG as established by FISH and 19 MPM tumor cell lines without C-MYC CNG as established by FISH. **** p < 0.0001. E, The 
box plots depict relative CNG of PVT1 by q-PCR in 11 MPM tumor cell lines with C-MYC CNG as established by FISH and 19 
MPM tumor cell lines without C-MYC CNG as established by FISH. *** p < 0.001. Normalized mRNA expression analysis of F 
C-MYC and G PVT1 transcript using Affymetrix U133 plus 2.0 chips in MPM tumor specimens compared with normal samples. 
**** p < 0.0001, ** p < 0.01. FISH, fluorescence in situ hybridization; MPM, malignant plural mesothelioma; CNG, copy number 
gain; q-PCR, quantitative polymerase chain reaction.
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DISCUSSION
Our results show that amplification of the 8q24 chromo-
somal region occurs frequently in MPM cell lines and tumor 
specimens. Our in vitro findings suggest that C-MYC and PVT1 
CNG may promote a malignant MPM phenotype. We have 
demonstrated that C-MYC and PVT1 knockdown by siRNA 
both increased cisplatin sensitivity and reduced cell prolifera-
tion capabilities in MPM cell lines. Interestingly, induction of 
apoptosis (as assessed by PARP-C levels) was observed only 
after PVT1 knockdown and not after C-MYC knockdown. In 
addition, our analysis of the expression of apoptosis-related 
genes revealed that C-MYC helps to maintain a regulatory bal-
ance between the expression of pro- and antiapoptotic genes, 
whereas PVT1 showed a trend toward up-regulating proapop-
totic genes and down-regulating antiapoptotic genes. These 
findings suggest that the two genes have differing functions: 
although C-MYC CNG stimulates proliferation and helps to 
decrease sensitivity to cisplatin platinum therapy, PVT1 CNG 
stimulates proliferation, decreases sensitivity to platinum 
therapy, and suppresses apoptosis. PVT1 CNG can also con-
tribute to the overexpression of miRNAs contained within this 
locus; we extended our study to include one of the most highly 
expressed of these miRNAs—miR-1204.
The 8q24 chromosomal region is frequently amplified 
in many tumors. This regional amplification leads to coam-
plification of the C-MYC and PVT1 genes located in this 
region.19,25 C-MYC encodes a transcription factor that regu-
lates the expression of multiple genes involved in cellular 
processes such as growth, apoptosis, proliferation, and dif-
ferentiation.15–17 Deregulated C-MYC expression, which has 
been detected in a wide variety of human tumors, promotes 
tumorigenesis by increasing genomic instability, induces 
proliferation and apoptosis, stimulates angiogenesis and 
migration, and promotes adaptation to a hypoxic microenvi-
ronment.17 We found C-MYC CNG to be highly frequent in 
MPM cell lines and tumor specimens. However, we did not 
find a correlation between C-MYC CNG with clinicopatho-
logical features on the one hand and patient outcomes on the 
other hand. The fact that we did not find a correlation may be 
due to the great aggressiveness of these tumors, which makes 
it difficult to obtain detailed clinical treatment and long-term 
follow-up data for these patients.
C-MYC knockdown increases cisplatin sensitivity 
and decreases cell proliferation in MSTO-211H cell lines. 
Several studies have reported that MYC-mediated transcrip-
tion is involved in the regulation of multiple genes, includ-
ing genes involved in regulating cell cycle progression such 
as cyclin-dependent kinases (CDKs) as CDK1, CDK2, CDK4, 
and CDK6, among others.26–29 Interestingly, we observed that 
C-MYC knockdown also induces a PARP-cleaved decrease, 
suggesting that C-MYC CNGs could induce apoptosis in 
MPM. How C-MYC regulates apoptosis is a matter of contin-
ued debate. It is accepted that C-MYC triggers apoptosis and 
that its overexpression may help to sensitize cells to undergo 
apoptosis.30–32 It has been shown in vitro that the withdrawal 
of growth factors in cells down-regulates C-MYC, inducing 
cell cycle arrest, whereas C-MYC overexpression rapidly 
induces apoptosis.32 C-MYC regulates different target genes 
under specific conditions and in a tissue-specific manner to 
regulate apoptosis.14 We have shown that C-MYC knockdown 
tends to keep a balance between up- and down-regulation of 
the expression of pro- and antiapoptotic genes (Table 1).
PVT1 is frequently coamplified with C-MYC in many 
tumors, acts as an oncogene that noncoding RNA and a clus-
ter of at least six miRNAs that span the PVT1 region recently 
have been identified.12,21 PVT1 has been described as an MYC 
activator33 and as a downstream target of both the C-MYC and 
N-MYC genes.34 We found that C-MYC knockdown down-
regulates PVT1 in MSTO-211H and H28 cell lines, suggest-
ing rather than C-MYC might regulate PVT1 gene expression 
in MPM cell lines. In addition, PVT1 can regulate sensitivity 
to certain chemotherapeutic drugs (e.g., colleagues found that 
PVT1 inactivation increased gemcitabine sensitivity in human 
pancreatic cancer cells, contributing to cell survival and chemo-
resistance).23 PVT1 knockdown by siRNA in MSTO-211H cell 
lines increases cisplatin sensitivity and PARP-cleaved levels 
while decreasing proliferation/viability. These finding suggest 
that PVT1 can act as an oncogenic noncoding RNA and that 
PVT1 depletion by siRNA induces a change in gene expression 
that enhances response to chemotherapy and induces apoptosis.
In addition, by analyzing the expression of apoptosis-
related genes, we demonstrated that PVT1 knockdown up-
regulated genes involved in proapoptotic functions (LTB, 
BCL2L14, PYCAR, FASLG, and TNFRSF1B) and down-reg-
ulated genes involved in antiapoptotic functions (BCL2L1, 
BCL2, ICEBERG, and BIRC8). It therefore appears that 
PVT1 depletion favors an apoptotic phenotype. In addition, 
we characterized the expression of miRNAs spanning the 
PVT1 region in MPM cell lines, showing different expres-
sion levels of these miRNAs in MPM cell lines and high-
lighting miR-1204 overexpression in MSTO-211H cell lines 
with PVT1 CNG. We also found that miR-1204 depletion 
promotes the expression of antiapoptotic genes. This find-
ing suggests that PVT1 CNGs, together with the action of 
miRNAs in this region, can contribute to survival and che-
moresistance in MPM.
In summary, our findings indicate that C-MYC and 
PVT1 coamplification is frequent in MPM. C-MYC and PVT1 
cooperation helps to stimulate proliferation, decrease sensitiv-
ity to platinum therapy, and reduce apoptosis. Both genes also 
help to regulate apoptosis-related genes, with C-MYC reveal-
ing a tendency to maintain a balance between proapoptotic 
and antiapoptotic genes, whereas PVT1 revealed a tendency to 
up-regulate proapoptotic genes and down-regulate antiapop-
totic genes, thereby helping to suppress apoptosis.
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